CDK7-IN-2
Modify Date: 2024-01-09 15:37:35
CDK7-IN-2 structure
|
Common Name | CDK7-IN-2 | ||
|---|---|---|---|---|
| CAS Number | 2326428-19-5 | Molecular Weight | 497.63 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H39N7O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CDK7-IN-2CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1]. |
| Name | CDK7-IN-2 |
|---|
| Description | CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1. |
| Molecular Formula | C26H39N7O3 |
|---|---|
| Molecular Weight | 497.63 |